Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | TSPO | P30536 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20970204 | 0.96 | PARP1 (0.50) | PARP1ADORA3ADORA1ADORA2ATMEM97 | |
| SCHEMBL20970140 | 0.96 | PARP1 (0.50) | PARP1ADORA3ADORA1ADORA2ATMEM97 | |
| SCHEMBL29501901 | 0.85 | ADORA3 (0.60) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL20970193 | 0.84 | PARP1 (0.46) | PARP1ADORA3ADORA1ADORA2ATMEM97 | |
| SCHEMBL20970121 | 0.83 | ADORA3 (0.56) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL19503480 | 0.76 | ADORA3 (0.48) | PARP1ADORA3ADORA1ADORA2ATMEM97 | |
| SCHEMBL20970142 | 0.75 | ADORA3 (0.47) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL20970111 | 0.75 | ADORA3 (0.47) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL20970141 | 0.74 | ADORA3 (0.43) | ADORA3ADORA1ADORA2ATMEM97DRD3 | |
| SCHEMBL20970112 | 0.73 | ADORA3 (0.43) | ADORA3ADORA1ADORA2ATMEM97DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072612-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200157097-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072612-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | PARP1 1103/4885ADORA3 486/4885ADORA1 289/4885 |
| US-20200157097-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | PARP1 1103/4885ADORA3 486/4885ADORA1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.